Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Mar 28, 2018 2:52pm
193 Views
Post# 27796991

This board is quiet...

This board is quiet...You should see all the bashing and nervoussness on the PLI board. Tonight the all year financials (2017) are presented, and PLI is waiting for FDA approval (or not) of RYPLAZIM.
Even when the nervoussness was HIGH here before approval, we never visited the dark world that those folks are sharing.........a visit is like a bad movie.

For TH, I read a lot of your posts. Some saying that the share price will visit 7$ again....that the stock is weak......but some talking advantage of buying under 9 $ (I am quite surpirse to see TH under 9$).

You know, my call is the same: do not sell one share. Why ? Because we never know (and its coming) when the most important news will be presented. And it will have more power than APPROVAL of TROGARZO. If we were happy with 30-40% on approval, my guess is that we will see more than that when the company will talk about the number of patients, the number of doctors prescribing TROGARZO. The share price will be like a burning house from there.

But everyone as a number in mind for the exit, or an entry point.

Good day.

FTV.
Bullboard Posts